<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;B01A&quot;,&quot;href&quot;:&quot;atc/B01A.md&quot;},{&quot;label&quot;:&quot;argatroban&quot;,&quot;href&quot;:&quot;drugs/drug_argatroban/&quot;},{&quot;label&quot;:&quot;Akimoto_2011 \u00b7 PD activated clotting time&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Argatroban_Cox2004_reference&quot;,&quot;label&quot;:&quot;Cox_2004_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_argatroban/Argatroban_Cox2004_reference.md&quot;,&quot;status&quot;:&quot;reviewed \u2014 candidate&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;Argatroban_Akimoto2011_reference&quot;,&quot;label&quot;:&quot;Akimoto_2011_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_argatroban/Argatroban_Akimoto2011_reference.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;pd_Cox_2004_ACT&quot;,&quot;label&quot;:&quot;Cox_2004 \u00b7 ACT&quot;,&quot;group&quot;:&quot;PD&quot;,&quot;href&quot;:&quot;drugs/drug_argatroban/pd_Cox_2004_ACT.md&quot;,&quot;status&quot;:&quot;reviewed \u2014 candidate&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false}]"></div>
<div class="pk-tab-mark" data-tab="Information"></div>

# activated clotting time — PD  <span class="pk-badge pk-badge--green">reviewed — candidate</span> <span class="pk-badge pk-badge--red" title="re-read by einfracz:gpt-oss-120b (not confirmed, agreement 0.556). Primary extraction retained.">cross-check: disputed</span>

<details class="pk-legend"><summary>PGx evidence and model availability</summary><table><tbody><tr><td><span class="pk-badge pk-badge--green">quantitative</span></td><td>Phenotype/genotype-specific effect on a named model parameter (θ).</td></tr><tr><td><span class="pk-badge pk-badge--neutral">qualitative</span></td><td>Gene–drug association without a quantitative parameter effect.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">guideline estimate</span></td><td>CPIC/DPWG-derived estimate, not a primary-paper estimate.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">safety allele</span></td><td>Adverse-reaction risk allele; no quantitative PK/PD parameter effect.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>the extraction is incomplete or inconsistent.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted.</td></tr><tr><td><span class="pk-badge pk-badge--green">▶ simulatable</span></td><td>Phenotype-specific browser simulation and downloadable PGx model available.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">model only</span></td><td>PGx model available; browser simulation unavailable.</td></tr></tbody></table></details>

<details class="legend">
<summary>Status and cross-check definitions</summary>
<table><thead><tr><th>Badge</th><th>Definition</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>Human-authored reference record or exemplar.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>Accepted extraction; applicable closed-form checks passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>Generated-model predictions agree with reported reference values; not human-verified.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>Replication accepted with unresolved advisory checks.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>Incomplete, inconsistent, or implausible extraction; values remain unverified.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>Model withheld because a core parameter uses a library default.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>Unaccepted record; displayed values remain unverified.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>Model generation pending or unavailable; not a validation verdict.</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>Review predates the current extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>All responding readers agree on all compared fields; fractions indicate agreeing/total readers.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>At least one non-structural discrepancy or incomplete reader agreement.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>At least one structural-parameter discrepancy; primary extraction retained pending review.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>Non-human or in-vitro evidence; parameters and simulations describe the stated experimental system.</td></tr></tbody></table>
<p><small><b>Status</b> reports validation and review outcomes; <b>cross-check</b> reports agreement between independent extractions. Agreement does not establish plausibility, model validity, or clinical applicability.</small></p>
</details>

## Record summary

**As extracted:** Argatroban (concentrations from this paper's PK model) drives activated clotting time (in s): direct sigmoid Emax (Hill) effect.

**Model:** Model available in **Models**; browser simulation unavailable.

> Argatroban plasma concentrations (ng/mL) directly stimulate the activated clotting time (ACT) via a sigmoidal Emax model with an additive effect, characterized by a baseline of 116 s, an Emax of 516 s, an EC50 of 4100 ng/mL, and a Hill constant of 0.87. The paper describes this as an immediate effect relationship where the drug concentration drives the increase in coagulation parameters, without specifying an effect compartment or indirect response mechanism.
>
> <sub>Source-based summary by qwen3.8:27b-mtp-q8_0 from the paper's text; not human-verified</sub>

- **paper:** `Akimoto_2011`
- **model family:** `sigmoid_emax`
- **driver:** `pk_record`
- **tier:** population
- **effect:** stimulation/additive

## Citation
Akimoto K et al., Anticoagulation with argatroban for ele…, Journal of clinical pharmac… (2011)
  ·  DOI: [10.1177/0091270010372627](https://doi.org/10.1177/0091270010372627)

## Parameters
| role | label (paper) | Q-code · name | value | unit | value_si | link | source |
|---|---|---|---|---|---|---|---|
| PD (effect) | E max | `Q320` · not captured | 516 | s | not captured | llm (not captured) | Akimoto_2011:pdv3 |
| PD (effect) | EC 50 | `Q321` · not captured | 4100 | ng/mL | not captured | llm (not captured) | Akimoto_2011:pdv3 |
| PD (effect) | Baseline | `Q324` · not captured | 116 | s | not captured | llm (not captured) | Akimoto_2011:pdv3 |
| PD (effect) | Hill constant | `Q325` · not captured | 0.87 | not captured | not captured | llm (not captured) | Akimoto_2011:pdv3 |
| variability | E max | `Q312` · not captured | 22 | %CV | not captured | llm (not captured) | Akimoto_2011:pdv3 |
| variability | EC 50 | `Q312` · not captured | 19 | %CV | not captured | llm (not captured) | Akimoto_2011:pdv3 |
| variability | Baseline | `Q312` · not captured | 17 | %CV | not captured | llm (not captured) | Akimoto_2011:pdv3 |
| variability | Hill constant | `Q312` · not captured | 32 | %CV | not captured | llm (not captured) | Akimoto_2011:pdv3 |

<details class="legend">
<summary>Parameter definitions</summary>
<table><thead><tr><th>Field</th><th>Definition</th></tr></thead><tbody><tr><td><code>label (paper)</code></td><td>Verbatim source label (label_verbatim).</td></tr><tr><td><code>Q-code · name</code></td><td>Matched ontology identifier and parameter name; e.g. Q22: clearance, Q27: CL/F, Q49: ka.</td></tr><tr><td><code>value</code></td><td>Reported parameter estimate.</td></tr><tr><td><code>unit</code></td><td>Verbatim source unit (unit_verbatim).</td></tr><tr><td><code>value_si</code></td><td>Normalised estimate; absent when unit conversion is unavailable.</td></tr><tr><td><code>link</code></td><td>Ontology-mapping method and confidence. exact/boundary/fuzzy/tv_prefix/caption_compartment/special_case: deterministic; llm/llm_confirmed/llm_corrected: LLM-assisted; review/review_gapfill: secondary-review source; boundary_relink: corrected mapping.</td></tr><tr><td><code>source</code></td><td>Source location: colN (table column), other_prose (text), review (secondary source), or pgx (PGx record).</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>Not recorded; not equivalent to zero.</td></tr><tr><td><code>—</code></td><td>Not applicable or not displayed.</td></tr><tr><td><code>not verified</code></td><td>Record not accepted; displayed estimates remain unverified.</td></tr></tbody></table>
</details>


## Exposure-response model

`Argatroban_Akimoto2011_PD_act` — sigmoid_emax, `response = E0 + Emax*frac`

| parameter | value (paper units) | SI |
|---|---|---|
| E0 | 116 s | 116 s |
| Emax | 516 s | 516 s |
| EC50 | 4100 ng/mL | 0.0041 kg/m3 |
| gamma | 0.87 | — |

Closed-form check points (response, SI): `at_0` = 116, `at_EC50` = 374, `at_inf` = 632

## Review

Verdict <span class="pk-badge pk-badge--green">reviewed — candidate</span>

| check | status | note |
|---|---|---|
| `T0_driver` | pass | driver is the drug, a synonym or one of its metabolites (or unnamed) |
| `T1_closed_form` | pass | engineer's check points reproduced from the bound parameters |
| `T1b_fmu` | skipped | template FMU / fmpy not available — advisory only |
| `T2_direction` | pass | the response rises, as direct effect predicts |
| `T3_plausibility` | pass | EC50, gamma, Imax and baseline in range |
| `T4_defaults` | pass | nothing defaulted |


**Cross-check (independent readings):** <span class="pk-badge pk-badge--red">cross-check: disputed</span>  
Primary extraction: `ollama:qwen3.8:27b-mtp-q8_0`; retained regardless of cross-check verdict.

| second reader | verdict | agreement | disagreements |
|---|---|---|---|
| `einfracz:gpt-oss-120b` | not confirmed | 0.556 (5/9 fields) | 4 |

<details><summary>4 field discrepancies</summary>

| second reader | field | first reading | second reading | agreement |
|---|---|---|---|---|
| `einfracz:gpt-oss-120b` | `effect_direction` | stimulation | inhibition | mismatch |
| `einfracz:gpt-oss-120b` | `parameters[Q320]` | 516 | not captured | only_one_extracted |
| `einfracz:gpt-oss-120b` | `parameters[Q323]` | not captured | 516 | only_one_extracted |
| `einfracz:gpt-oss-120b` | `parameters[Q325].value` | 0.87 | 1.8 | mismatch |

</details>

<details class="legend">
<summary>Cross-check definitions</summary>
<table><thead><tr><th>Field</th><th>Definition</th></tr></thead><tbody><tr><td><code>second reader</code></td><td>Additional extraction model; the default uses a different model family. Multiple readers are supported.</td></tr><tr><td><code>agreement</code></td><td>Proportion of compared fields in agreement.</td></tr><tr><td><code>verdict</code></td><td>confirmed: full agreement; partly confirmed: non-structural discrepancy; not confirmed: structural discrepancy; primary re-run: hinted retry after an empty primary extraction.</td></tr><tr><td><code>combined</code></td><td>Confirmed only when all responding readers agree; a structural discrepancy makes the result disputed.</td></tr><tr><td><code>kept</code></td><td>Primary extraction retained; discrepancies require review rather than automatic replacement.</td></tr></tbody></table>
</details>


<div class="pk-tab-mark" data-tab="Models"></div>

## Model downloads

<div class="pk-models-grid"><div class="pk-models-table">
<table class="pk-models"><thead><tr><th>format</th><th>archive contents</th><th>download</th></tr></thead><tbody>
<tr><td><b>Modelica</b></td><td><code>.mo</code> + Modelica script</td><td><a href="drugs/drug_argatroban/Argatroban_Akimoto2011_PD_act/Argatroban_Akimoto2011_PD_act_modelica.zip" download>Argatroban_Akimoto2011_PD_act_modelica.zip</a> <span class="pk-size">(2.9 kB)</span></td></tr>
<tr><td><b>FMI 2.0 (FMU)</b></td><td><code>.fmu</code> + fmpy driver</td><td><span class="pk-missing">unavailable</span></td></tr>
<tr><td><b>MATLAB &amp; GNU Octave</b></td><td><code>.m</code> ODE function + driver</td><td><a href="drugs/drug_argatroban/Argatroban_Akimoto2011_PD_act/Argatroban_Akimoto2011_PD_act_matlab.zip" download>Argatroban_Akimoto2011_PD_act_matlab.zip</a> <span class="pk-size">(3.0 kB)</span></td></tr>
<tr><td><b>MATLAB (SimBiology)</b></td><td><code>.sbproj</code> + driver</td><td><span class="pk-missing">unavailable</span></td></tr>
<tr><td><b>SBML</b></td><td><code>.xml</code> (L3V2) + Python driver</td><td><a href="drugs/drug_argatroban/Argatroban_Akimoto2011_PD_act/Argatroban_Akimoto2011_PD_act_sbml.zip" download>Argatroban_Akimoto2011_PD_act_sbml.zip</a> <span class="pk-size">(2.4 kB)</span></td></tr>
<tr><td><b>CellML</b></td><td><code>.cellml</code> + Python driver</td><td><a href="drugs/drug_argatroban/Argatroban_Akimoto2011_PD_act/Argatroban_Akimoto2011_PD_act_cellml.zip" download>Argatroban_Akimoto2011_PD_act_cellml.zip</a> <span class="pk-size">(2.4 kB)</span></td></tr>
</tbody></table>
<p>Archives contain model source, a simulation script, and execution instructions.</p>
</div></div>

<div class="pk-tab-mark" data-tab="Simulation"></div>

_Browser simulation unavailable: no shared WebAssembly template. The **Models** tab provides the record-specific FMI archive._

<div class="pk-tab-end"></div>

---
<sub>← back to [argatroban](drugs/drug_argatroban/)</sub>
